Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arrowhead Pharmaceuticals Inc ARWR

Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform... see more

Recent & Breaking News (NDAQ:ARWR)

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

Business Wire May 15, 2023

Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results

Business Wire May 2, 2023

Arrowhead Pharmaceuticals' Proprietary Pulmonary TRiM(TM) Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect

Business Wire April 25, 2023

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results

Business Wire April 18, 2023

Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics

Business Wire April 12, 2023

First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead

Business Wire April 4, 2023

Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK

Business Wire April 3, 2023

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire March 31, 2023

Arrowhead Receives FDA Fast Track Designation for ARO-APOC3

Business Wire March 20, 2023

Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference

Business Wire March 3, 2023

Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Business Wire February 28, 2023

Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

Business Wire February 15, 2023

Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results

Business Wire February 6, 2023

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis

Business Wire February 2, 2023

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results

Business Wire January 25, 2023

Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

Business Wire December 21, 2022

Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

Business Wire December 21, 2022

Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen

Business Wire December 20, 2022

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire December 15, 2022

Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Business Wire December 8, 2022